Videos
Watch our experts break down complex topics and suggest ways to adjust your business. Gain clarity, step-by-step.
Inside Compendia: Off-Label Applications
Avalere Health Advisory experts discuss how compendium shape off-label drug use, underscoring both benefits and risks in clinical decision-making.
Inside Compendia: Expanding Intended Use Populations
In the second installment of our Inside Compendia series, Avalere Health Advisory experts discuss how compendia can support clinical decision-making and medication access, highlighting a case study on GLP-1s.
Inside Compendia: Introduction to Clinical Drug Compendia
In the first installment of our Inside Compendia series, Avalere Health Advisory experts discuss how to engage and support life sciences companies in ways of incorporating their products into clinical compendia and guidelines.
Inside the Latest RADV Regulatory Developments
Avalere Health Advisory experts break down major updates to the CMS Medicare Advantage (MA) Risk Adjustment Data Validation (RADV) audit process, including enhanced technology, workforce expansion, and increased audit volume, and how health plans can prepare.
Unpacking the Final CY2026 CMS Part C and D Rule and Rate Announcement
Avalere Health Advisory experts explore how the Trump Administration approached Medicare Advantage and Medicare Part D policies proposed by the Biden Administration, ranging from anti-obesity medication coverage to plan payment increases
Unpacking CMS RADV: The Selection Process and Planning for the Future
Avalere experts discuss the CMS Medicare Advantage (MA) Risk Adjustment Data Validation (RADV) audit process and provide insight on how health plans can proactively plan and prepare for these audits.
AI for Health Plans: AI and Clinical Data in Action
In the third and final installment of our AI for health plans video series, Avalere is joined by experts Mia Bolton and Teddy Gedamu from Tenasol to share real-world examples of how artificial intelligence (AI) can streamline data management and improve decision-making in health plans.
AI for Health Plans: Harnessing AI to Optimize Clinical Data
In the second installment of our AI for health plans video series, Avalere is joined by experts Mia Bolton and Teddy Gedamu from Tenasol to discuss how plans are operationalizing enterprise clinical data.
AI for Health Plans: Unlocking the Power of Clinical Data
In the first installment of our AI for health plans video series, Avalere is joined by experts Mia Bolton and Teddy Gedamu from Tenasol to discuss the regulatory and market dynamics around clinical data and what this means for health plans.
Kidney Care Agenda: Fall 2024
Ahead of the American Society of Nephrology Kidney Week, Avalere experts dive into the key regulatory and legislative developments related to kidney disease that expect to see action in the remaining weeks of 2024.
The Evolution of Lactation Care
In this installment of our women's health video series, Sarah Kellogg Neff, CEO of the Lactation Network, joins Avalere to explore the value of access to lactation services.
Innovations in Fertility and Family-Forming Care
In this installment of our women's health video series, Avalere is joined by Jessica Bell van der Wal, co-Founder and CEO of Frame Fertility, for a discussion of the myths, challenges, and future surrounding family-forming care.
The Impact of Caregiving on Mental Health
In the first installment of our women's health video series, Avalere sits down with Dr. Madhavi Vemireddy of caregiving platform Cleo to discuss the impact caregiving can have on one’s mental health.
Key NCCN Sessions Impacting Market Access to Oncology Care
In this video, Avalere market access experts discuss major takeaways from the 2024 NCCN (National Comprehensive Cancer Network) Annual Conference in the areas of reimbursement, early detection of cancer, consideration of a broader pool as provider decision makers, and patient involvement in their care decisions.
IRA Impacts on Market Access Strategy
Ahead of Asembia 2024, Avalere market access experts discuss the potential impacts of IRA provisions, including Part D redesign and Medicare drug price negotiation, on go-to-market and contracting strategy.
Discussing Value at Asembia and ISPOR
Ahead of the upcoming Asembia and ISPOR conferences, Avalere experts discuss the role of external assessors in value assessment.
Mitigating and Preventing Drug Shortages
Avalere experts provide insights on the dynamics and policy proposals surrounding recent drug shortages.
The Evolution of Value Requirements
Ahead of Asembia 2024, Avalere experts discuss the evolution of biopharmaceutical value requirements and how organizations will need to evolve their business models accordingly.
Avalere’s Insights on Rare Disease
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts summarize key learnings for pharmaceutical companies to consider.
How Policies Shape the Rare Disease Treatment Landscape
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts explore policies shaping rare disease drug development and access.